Navigation Links
Subsidies For GPs' Visits : Agreement Reached

Dialogues between District Health Boards and Primary Health Organisations, (PHOs), which faced difficulties late last month, has now been resolved //, with both parties reaching an agreement on the extension of subsidies for doctors' visits.

An estimated 680,000 New Zealanders who are GP patients, aged between 45 - 64 years, are expected to benefit from July 1.

DHBs and GPs have long been at loggerheads over the conditions, with the GPs refusing to sign a proposed agreement concerning the subsidy rollout, saying it was an attempt to control their fees.

The new agreement does not require GPs to acquire approval of future fee increases , instead , strengthens review mechanisms of fees. It directs GPs to be advised on refund of fees if patients are considered to have paid an extra amount, says Radio New Zealand's health correspondent.Family doctors are required to publicise their fees under the deal.

Health Minister, Pete Hodgson, says that the agreement will ensure that the subsidy is ' not misappropriated’ and adds that the indications are that the majority of PHOs will sign the agreement.

Peter Foley, GPs' spokesman, says he's pleased that commonsense has prevailed.


'"/>




Page: 1

Related medicine news :

1. Agricultural Subsidies Responsible For Obesity, Says Expert
2. New Zealand’s Pharmac Subsidies Two More HIV Drug
3. Prime Minister Visits the Proposed Super Hospital Site
4. Door-to-door Visits to Check Water-borne and Seasonal Diseases in Rajasthan
5. Agreement To Speed Up Development of Bird flu vaccine
6. MIOT Hospital Signs Agreement With German Healthcare Facility
7. Strained Economic Agreement Between Singapore And India
8. Ranbaxy Signs Agreement With Zenotech For Cancer Drugs
9. Agreement for Joint Trials of Avian Flu Vac cine on Humans
10. Ranbaxy Signs Licensing, Supply Agreement for Canadian Market
11. Indo-Fiji Agreement in Field of Health, Medicine Approved
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/16/2017)... Lewisville, TX (PRWEB) , ... August 16, 2017 , ... ... in the United States, named Dr. Douglas J. Harrison, as the new Medical Director ... will be the new facility Medical Director of our Sienna Plantation location,” said Dr. ...
(Date:8/16/2017)... ... , ... “God Will Break Every Chain”: an inspirational story for those shackled by the chains ... author, Evangelist Joann Shivers, a writer and a woman of great faith and wisdom. ... early age. She was born and raised in Vero Beach, Florida and has dedicated ...
(Date:8/15/2017)... ... August 15, 2017 , ... The first study to ... multiple myeloma has been completed, with the team’s findings now published online ahead of ... , Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Progressive Dental, a leading ... on the 2017 Fast 50 list of Fastest Growing Companies in Tampa Bay. The ... area who has shown three consecutive years of growth. For this year’s award, Progressive ...
(Date:8/15/2017)... ... August 15, 2017 , ... Dr. Timothy Davis ... periodontal disease . This information can be used to develop patient-specific treatment ... The two salivary diagnostic tests, named MyPerioPath® and MyPerioID® are offered by OralDNA® ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... June 30, 2017, and updated its financial outlook for ... For the fiscal third quarter, Hill-Rom reported earnings of ... share in the prior-year period. These results reflect after-tax ... share primarily related to the non-cash write-down of assets ...
(Date:7/27/2017)... Pa., July 27, 2017  West Pharmaceutical Services, Inc. ... results for the second-quarter 2017 and updated financial guidance ... Second-Quarter 2017 Highlights Reported net ... over the prior-year quarter. Net sales at constant currency ... reported-diluted EPS was $0.51, compared to $0.60 in the ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: